Dermira Inc. (DERM) Given “Buy” Rating at Needham & Company LLC
Dermira Inc. (NASDAQ:DERM)‘s stock had its “buy” rating reaffirmed by Needham & Company LLC in a research note issued to investors on Wednesday.
Other equities analysts have also issued reports about the stock. Leerink Swann reaffirmed a “buy” rating and set a $47.00 price target (up from $46.00) on shares of Dermira in a research report on Thursday, June 2nd. Zacks Investment Research raised shares of Dermira from a “sell” rating to a “hold” rating in a report on Friday, July 8th. Finally, Wedbush raised their target price on shares of Dermira from $42.00 to $46.00 and gave the company an “outperform” rating in a report on Thursday, June 2nd. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $41.00.
Dermira (NASDAQ:DERM) traded down 1.60% during midday trading on Wednesday, hitting $35.00. 81,068 shares of the company were exchanged. The firm’s 50-day moving average price is $32.35 and its 200-day moving average price is $28.45. The stock’s market capitalization is $1.24 billion. Dermira has a one year low of $17.42 and a one year high of $36.16.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/dermira-inc-derm-given-buy-rating-at-needham-company-llc-2.html
Dermira (NASDAQ:DERM) last released its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.89) EPS for the quarter, missing analysts’ consensus estimates of ($0.86) by $0.03. Equities research analysts anticipate that Dermira will post ($3.39) earnings per share for the current year.
In other Dermira news, insider Eugene A. Bauer sold 2,500 shares of the firm’s stock in a transaction dated Friday, July 1st. The shares were sold at an average price of $29.48, for a total value of $73,700.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Andrew Guggenhime sold 15,000 shares of the firm’s stock in a transaction dated Monday, September 19th. The shares were sold at an average price of $35.01, for a total transaction of $525,150.00. Following the completion of the transaction, the chief financial officer now directly owns 20,116 shares in the company, valued at $704,261.16. The disclosure for this sale can be found here. 17.30% of the stock is currently owned by company insiders.
A number of institutional investors have recently added to or reduced their stakes in DERM. Schwab Charles Investment Management Inc. increased its stake in Dermira by 30.1% in the second quarter. Schwab Charles Investment Management Inc. now owns 62,986 shares of the biopharmaceutical company’s stock worth $1,843,000 after buying an additional 14,566 shares during the last quarter. American Century Companies Inc. bought a new stake in Dermira during the second quarter worth $1,352,000. Metropolitan Life Insurance Co. NY increased its stake in Dermira by 25.5% in the second quarter. Metropolitan Life Insurance Co. NY now owns 15,819 shares of the biopharmaceutical company’s stock worth $463,000 after buying an additional 3,210 shares during the last quarter. Point72 Asset Management L.P. increased its stake in Dermira by 66.5% in the second quarter. Point72 Asset Management L.P. now owns 127,700 shares of the biopharmaceutical company’s stock worth $3,735,000 after buying an additional 51,000 shares during the last quarter. Finally, Iguana Healthcare Management LLC increased its stake in Dermira by 172.7% in the second quarter. Iguana Healthcare Management LLC now owns 150,000 shares of the biopharmaceutical company’s stock worth $4,388,000 after buying an additional 95,000 shares during the last quarter. 82.46% of the stock is currently owned by hedge funds and other institutional investors.
Dermira, Inc is a biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies for dermatologic diseases. The Company’s portfolio includes three late-stage product candidates that target unmet needs and market opportunities, such as Cimzia (certolizumab pegol), DRM04 and DRM01.
Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with MarketBeat.com's FREE daily email newsletter.